Target Therapeutic Digoxin Level: 0.5-0.9 ng/mL
The target therapeutic serum digoxin concentration for heart failure is 0.5-0.9 ng/mL, which is lower than the historically used range of 0.8-2.0 ng/mL. 1 This narrower therapeutic window is based on retrospective analyses showing that lower concentrations (0.5-0.9 ng/mL) provide equivalent efficacy for preventing worsening heart failure while minimizing toxicity risk.
Therapeutic Range Interpretation
The FDA label acknowledges a broader range of 0.8-2.0 ng/mL for "adequately digitalized" patients, but emphasizes that clinical benefits can occur even below this range 2. However, current ACC/AHA guidelines specifically recommend targeting 0.5-0.9 ng/mL based on evidence that higher levels do not provide superior outcomes 1.
Key Concentration Thresholds:
- Subtherapeutic: <0.5 ng/mL (may still provide clinical benefit)
- Therapeutic target: 0.5-0.9 ng/mL
- Elevated but potentially tolerated: 0.9-2.0 ng/mL
- Toxic range: >2.0 ng/mL (though toxicity can occur at lower levels)
Toxicity Recognition and Risk Factors
Overt digoxin toxicity is commonly associated with serum levels >2 ng/mL 1, but approximately one-third of patients with clinical toxicity have concentrations <2.0 ng/mL 2. This means you cannot rule out digoxin toxicity based solely on a level below 2.0 ng/mL.
Clinical Manifestations of Toxicity:
- Cardiac: Arrhythmias (ectopic rhythms, re-entrant rhythms, heart block)
- Gastrointestinal: Anorexia, nausea, vomiting
- Neurological: Visual disturbances (yellow-green halos), disorientation, confusion
Conditions That Lower the Toxicity Threshold:
Even with "therapeutic" digoxin levels, toxicity risk increases substantially with:
A recent study found that high creatinine and abnormal potassium levels (both low and high) significantly increased the likelihood of toxic digoxin concentrations 3.
Drug Interactions That Elevate Digoxin Levels
Reduce digoxin dose by 30-50% when initiating these medications 1:
- Amiodarone (reduce dose by 30-50%)
- Dronedarone (reduce dose by at least 50%)
- Verapamil
- Quinidine
- Propafenone
- Clarithromycin/Erythromycin
- Itraconazole/Posaconazole/Voriconazole
- Cyclosporine
Recent pharmacokinetic analysis specifically identified N-desethylamiodarone (amiodarone's metabolite) as reducing digoxin clearance by 3% for every 100 ng/mL increase 4. For patients on amiodarone with N-desethylamiodarone >600 ng/mL and creatinine clearance ≤30 mL/min, digoxin doses as low as 0.03125 mg daily may be required.
Proper Timing of Serum Sampling
Critical timing requirement: Sample must be drawn at least 6-8 hours after the last dose, preferably just before the next scheduled dose 2. This allows adequate time for equilibration between serum and tissue.
Common pitfall: Sampling too early (within 6 hours) will yield falsely elevated levels due to incomplete tissue distribution, potentially leading to inappropriate dose reductions 2.
On once-daily dosing, concentrations will be 10-25% lower at 24 hours versus 8 hours post-dose, depending on renal function 2.
Dosing Recommendations
Standard maintenance dose: 0.125-0.25 mg daily 1, 5, 6
Use lower doses (0.125 mg daily or every other day) for:
- Age >70 years
- Impaired renal function (adjust based on creatinine clearance)
- Low lean body mass
- Concomitant use of interacting medications 1
Higher doses (0.375-0.50 mg daily) are rarely needed or appropriate 1. Loading doses are not recommended for chronic heart failure management 1.
Management of Abnormal Levels
Subtherapeutic Levels (<0.5 ng/mL):
Do not automatically increase the dose. Assess clinical response first—many patients achieve symptom control at levels below 0.5 ng/mL 2. Consider dose adjustment only if:
- Patient has worsening heart failure symptoms
- Inadequate rate control in atrial fibrillation
- Confirmed medication adherence
Elevated but Non-Toxic Levels (0.9-2.0 ng/mL):
- Assess for early toxicity symptoms
- Check electrolytes (especially potassium and magnesium)
- Review for drug interactions
- Consider dose reduction, particularly if level >1.2 ng/mL given mortality data
- Recheck level in 1 week after any dose adjustment
Toxic Levels (>2.0 ng/mL) or Clinical Toxicity:
- Immediately discontinue digoxin
- Check complete metabolic panel (potassium, magnesium, calcium, renal function)
- Obtain ECG to assess for arrhythmias
- Correct hypokalemia cautiously (avoid rapid correction which can worsen toxicity)
- Correct hypomagnesemia
- Consider digoxin-specific antibody fragments (Digibind/DigiFab) for:
- Life-threatening arrhythmias
- Severe hyperkalemia (K+ >5.5 mEq/L)
- Hemodynamic instability
- Ingestion of massive overdose
Monitoring Frequency
Routine monitoring of digoxin levels is not necessary in stable patients with good clinical response 1, 2. The radioimmunoassay was developed to evaluate toxicity, not efficacy.
Check digoxin level when:
- Suspected toxicity (symptoms present)
- Significant change in renal function
- Initiation of interacting medications
- Poor clinical response despite adequate dosing
- After 1 week of therapy if patient has chronic kidney disease or acute kidney injury 7
Special Populations
Elderly patients: Exercise particular caution as they commonly have reduced renal function even with normal serum creatinine, low lean body mass, and are more susceptible to toxicity 1, 3.
Renal impairment: Digoxin clearance correlates directly with creatinine clearance. Use the Cockcroft-Gault formula to estimate clearance and adjust dosing accordingly 2. Recent data shows creatinine levels significantly affect toxic concentration risk 3.
Atrial fibrillation: While digoxin can be used for rate control, beta-blockers are usually more effective, particularly during exercise 1. The optimal therapeutic range for digoxin in atrial fibrillation has not been established 7.